Accurate Detection of anti-CD19 CAR-T Cells
Application of R19M, An FMC63 scFv Idiotype Monoclonal Antibody
Anti-CD19 CAR-T cell therapy
With the development of cancer immunotherapy, Chimeric AntigenReceptor (CAR)-T cell, […]
Is CD3ζ alone in CAR structure good enough?
Two CD19-specific CARs approved by US FDA in 2017 have induced prominent responses in patients with refractory leukemia and lymphomas. However, Grade 3/4 CRS and ICANS were reported in proportion […]
Team up: CAR T meets Immune Checkpoint Inhibitor
Immune checkpoint inhibitor was undoubtedly a breakthrough in cancer therapy. Since FDA approved Pembrolizumab and Nivolumab for melanoma in 2014, PD-1/PD-L1 blockade has been proven to be effective […]
